Merck + Co., Inc.

Xenon Pharmaceuticals Inc.

Mitokinin, Inc.

Icahn School of Medicine at Mount Sinai

Attenua, Inc.

University of California

Robert Joseph Devita

Matthew J Wyvratt

Christoph Martin Dehnhardt

Mark T Goulet

Sultan Chowdhury

Jonathan R Young

Alla Yurevna Zenova

Thilo Focken

William R Schoen

Michael Edward Grimwood

Jean-Christophe Andrez

Kristen Nicole Burford

Syed Abid Hasan

James Philip Johnson, Jr

James Roy Empfield

Charles Jay Cohen

Michael H Fisher

Daniel De Roulet

Thomas F Walsh

Jinlong Jiang

Eric E Allen

Andrew F Stewart

Kunal Kumar

Kevan M Shokat

Feroze Ujjainwalla

David Earl Bogucki

Qi Jia

Richard J Bochis

Michael Scott Wilson

Richard B Toupence

Roy G Smith

Shannon Marie Decker

Peng Wang

Nicholas T Hertz

Roberto J Sanchez

Yi Tien Yang

Roberto Sanchez

Brendan J Canning

Avner Schlessinger

Peter Man-Un Ung

Hui Wang

Hailing Li

Chalada Suebsuwong

Alison J Frontier

Adolfo Garcia Ocaña

Jing Liang

Peter Dicpinigaitis

Described herein are compounds having the following structure: formula (I) or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof. Also disclosed are compositions containing the compounds, methods of inhibiting activity of DYRK1 A in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

Kinase inhibitor compounds and compositions and methods of use

The present invention is directed to kinase inhibitor compounds having the following structure: or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R, R, X, n, R, Y, Z, R, R, R, and = are as defined herein. The present invention also relates to compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder. 

The present disclosure is directed, in part, to substituted purines, or pharmaceutically acceptable salts thereof, represented by formula (VIII): for the treatment and/or prevention of neurodegenerative disease, mitochondrial disease, fibrosis, and/or cardiomyopathy.

Substituted purines for the treatment of neurodegenerative and mitochondrial diseases

This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Benzenesulfonamide compounds and their use as therapeutic agents

This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

Benzenesulfonamide compouds and their use as therapeutic agents

The disclosure is directed to compounds and pharmaceutically acceptable salts thereof for the treatment and/or prevention of neurodegenerative and/or mitochondrial diseases, such as Parkinson's disease and Leigh's disease. The compounds and pharmaceutically acceptable salts thereof are of the class of nitrogenous bases, for example, pyrimidines, purines, pteridines, and pharmaceutically acceptable salts thereof.

Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease

This invention is directed to methods of preparing benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

The disclosure is directed to compounds and pharmaceutically acceptable salts thereof for the treatment and/or prevention of neurodegenerative and/or mitochondrial diseases, such as Parkinson's disease and Leigh's disease. The compounds and pharmaceutically acceptable salts thereof are of the class of nitrogenous bases, for example, pyrimidines, purines, pteridines and pharmaceutically acceptable salts thereof.

Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease

Disclosed herein are compositions which include nicotinic receptor agonists, specifically of the &#x3b1;7 nAChR subtype, and methods for suppressing cough.

Antitussive compositions and methods

The present invention is directed to certain naphtho-fused lactams of the general structural formula:

Naphtho-fused lactams promote release of growth hormone

Antagonists of gonadotropin releasing hormone

Growing community of inventors

Westfield, NJ, United States of America

Robert Joseph Devita